Significantly, prior reports indicate that even with longer follow up (8–9 months), p16p19-deficiency or oncogenic Kras alone produces hematopoietic neoplasms (mostly B- or T-lymphomas and T cell leukemias) with relatively low efficiency [15], [29]. Here, KRAS is linked to lymphoma.